Source of Purines During Cancer Cell Breakdown
Purines released during cancer cell breakdown come from the intracellular nucleic acids (DNA and RNA) contained within the lysed tumor cells themselves. 1
Mechanism of Purine Release
When cancer cells undergo rapid lysis—whether from chemotherapy, radiation, or cytolytic antibody therapy—they release massive quantities of their intracellular contents into the bloodstream. Among these contents are nucleic acids, which are the primary source of purines in tumor lysis syndrome (TLS). 1
The Metabolic Pathway
The released purine nucleic acids follow a specific catabolic pathway:
- Purine nucleic acids (from DNA/RNA) → Hypoxanthine → Xanthine → Uric acid (via xanthine oxidase enzyme) 1
This metabolic cascade explains why hyperuricemia is a hallmark of TLS—the purines aren't coming from external sources but rather from the breakdown of the tumor cells' own genetic material.
Clinical Context and Implications
High tumor burden and rapid cell turnover create the greatest risk. Malignancies with high proliferative rates, large tumor burdens, and high chemosensitivity release the most purines upon treatment initiation. 1 This is why certain cancers carry higher TLS risk:
- Burkitt's lymphoma and lymphoblastic lymphomas (high risk)
- Acute leukemias with WBC >100,000 (high risk)
- Rapidly proliferating solid tumors with expected rapid treatment response (intermediate risk) 1
Why This Matters Clinically
Under normal physiologic conditions, the kidneys clear approximately 500 mg/day of uric acid. However, during massive tumor lysis, the sudden flood of purines from lysed cancer cells overwhelms this clearance capacity. 1 The resulting hyperuricemia leads to:
- Uric acid crystal precipitation in renal tubules (pH ~5 in distal tubules, where uric acid solubility is only ~15 mg/dL)
- Acute renal insufficiency or failure
- Potential for fatal complications if untreated 1
Important caveat: The purines are endogenous to the tumor cells—they are not absorbed from diet or synthesized de novo during the lysis event. This is why prophylactic strategies focus on either preventing uric acid formation (allopurinol blocking xanthine oxidase) or degrading already-formed uric acid (rasburicase converting it to more soluble allantoin). 1